Top

Published in:

03-02-2024 | Cancer Biomarker | Peritoneal Surface Malignancy

Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative

Authors: Nadege T. Fackche, MD, Ryan K. Schmocker, MD, MS, Richard Nudotor, MD, PMH, Boateng Kubi, BS, Jordan M. Cloyd, MD, Travis E. Grotz, MD, Keith F. Fournier, MD, Sean P. Dineen, MD, Jula Veerapong, MD, Joel M. Baumgartner, MD, MAS, Callisia N. Clarke, MD, Sameer H. Patel, MD, Gregory C. Wilson, MD, Laura A. Lambert, MD, Courtney Pokrzywa, MD, Daniel E. Abbott, MD, Byrne Lee, MD, Charles A. Staley, MD, Mohammad Y. Zaidi, MD, Fabian M. Johnston, MD, MHS, Jonathan B. Greer, MD

Published in: Annals of Surgical Oncology | Issue 5/2024

Abstract

Introduction

Patients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor oncologic outcomes after this procedure are limited. We aimed to determine the prognostic value of preoperative CEA, CA 125, and CA 19-9 on disease progression after CRS/HIPEC.

Methods

Patients with CRPM treated with curative intent CRS/HIPEC from 12 participating sites in the United States from 2000 to 2017 were identified. Progression-free survival (PFS), defined as disease progression or recurrence, was the primary outcome.

Results

In 279 patients who met inclusion criteria, the rate of disease progression was 63.8%, with a median PFS of 11 months (interquartile range [IQR] 5–20). Elevated CA 19-9 was associated with dismal PFS at 2 years (8.9% elevated vs. 30% not elevated, p < 0.01). In 113 patients who underwent upfront CRS/HIPEC, CA 19-9 emerged as the sole tumor marker independently predictive of worse PFS (hazard ratio [HR] 2.88, p = 0.048). In the subgroup of patients who had received neoadjuvant therapy (NAT), no variable was independently predictive of PFS. CA 19-9 levels over 37 U/ml were highly specific for accelerated disease progression after CRS/HIPEC. Lastly, there was no association between PFS and elevated CEA or CA 125.

Conclusions

Elevated CA 19-9 is associated with decreased PFS in patients with CRPM. While traditionally CEA is the main tumor marker assessed in colon cancer, we found that CA 19-9 may better inform preoperative risk stratification for poor oncologic outcomes in patients with CRPM. However, prospective studies are required to confirm this association.

Available only for authorised users

Koppe MJ, Boerman OC, Oyen WJG, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin. Ann Surg. 2006;243(2):212–22. https://doi.org/10.1097/01.sla.0000197702.46394.16.CrossRefPubMedPubMedCentral

Yang SY, Kang JH, Kim HS, Han YD, Min BS, Lee KY. Status of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. J Gastrointest Oncol. 2019;10(6):1251–65. https://doi.org/10.21037/jgo.2019.01.36.CrossRefPubMedPubMedCentral

Bakkers C, Lurvink RJ, Rijken A, et al. Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study. Ann Surg Oncol. 2021;28(13):9073. https://doi.org/10.1245/s10434-021-10190-z.CrossRefPubMedPubMedCentral

Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. https://doi.org/10.1200/JCO.2003.04.187.CrossRefPubMed

Klaver CEL, Musters GD, Bemelman WA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial. BMC Cancer. 2015;15:428. https://doi.org/10.1186/s12885-015-1430-7.CrossRefPubMedPubMedCentral

Cashin PH, Mahteme H, Spång N, et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer Oxf Engl. 1990;2016(53):155–62. https://doi.org/10.1016/j.ejca.2015.09.017.CrossRef

Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. https://doi.org/10.1245/s10434-008-9966-2.CrossRefPubMed

Sugarbaker PH. Surgical management of peritoneal carcinosis: diagnosis, prevention and treatment. Langenbecks Arch Chir. 1988;373(3):189–96. https://doi.org/10.1007/BF01274232.CrossRefPubMed

Spratt JS, Adcock RA, Muskovin M, Sherrill M, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40(2):256–60PubMed

10.

Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249(6):900–7.CrossRefPubMed

11.

Simkens GA, van Oudheusden TR, Luyer MD, et al. Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for Colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2015;22(8):2656–62. https://doi.org/10.1245/s10434-014-4297-y.CrossRefPubMed

12.

Ahmed S, Stewart JH, Shen P, Votanopoulos KI, Levine EA. Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. J Surg Oncol. 2014;110(5):575–84. https://doi.org/10.1002/jso.23749.CrossRefPubMed

13.

Zaidi MY, Lee RM, Gamboa AC, et al. Preoperative risk score for predicting incomplete cytoreduction: a 12-institution study from the US HIPEC collaborative. Ann Surg Oncol. 2020;27(1):156–64. https://doi.org/10.1245/s10434-019-07626-y.CrossRefPubMed

14.

Cashin PH, Graf W, Nygren P, Mahteme H. Patient selection for cytoreductive surgery in colorectal peritoneal carcinomatosis using serum tumor markers: An observational cohort study. Ann Surg. 2012;256(6):1078–83. https://doi.org/10.1097/SLA.0b013e318254f281.CrossRefPubMed

15.

Pelz JOW, Stojadinovic A, Nissan A, Hohenberger W, Esquivel J. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99(1):9–15. https://doi.org/10.1002/jso.21169.CrossRefPubMed

16.

Demey K, Wolthuis A, de van Buck Overstraeten A, et al. External validation of the prognostic nomogram (COMPASS) for patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2017;24(12):3604–8. https://doi.org/10.1245/s10434-017-6042-9.CrossRefPubMed

17.

Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66. https://doi.org/10.1016/S1470-2045(20)30599-4.CrossRefPubMed

18.

Wang WS, Lin JK, Chiou TJ, et al. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepatogastroenterology. 2002;49(43):160–4.PubMed

19.

Yu H, Son GM, Joh YG. The clinical significance of preoperative serum levels of carbohydrate antigen 19–9 in colorectal cancer. J Korean Surg Soc. 2013;84(4):231–7. https://doi.org/10.4174/jkss.2013.84.4.231.CrossRefPubMedPubMedCentral

20.

Takagawa R, Fujii S, Ohta M, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15(12):3433–9. https://doi.org/10.1245/s10434-008-0168-8.CrossRefPubMed

21.

Stojkovic Lalosevic M, Stankovic S, Stojkovic M, et al. Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients? Hell J Nucl Med. 2017;20(1):41–5. https://doi.org/10.1967/s002449910505.CrossRefPubMed

22.

Kaneko M, Ishihara S, Murono K, et al. Carbohydrate antigen 19–9 predicts synchronous peritoneal carcinomatosis in patients with colorectal cancer. Anticancer Res. 2017;37(2):865–70. https://doi.org/10.21873/anticanres.11391.CrossRefPubMed

23.

Rockall TA, McDonald PJ. Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. Int J Colorectal Dis. 1999;14(1):73–7. https://doi.org/10.1007/s003840050188.CrossRefPubMed

24.

Izquierdo FJ, Schuitevoerder D, Plana A, et al. The Chicago Consensus on peritoneal surface malignancies: management of colorectal metastases. Ann Surg Oncol. 2020;27(6):1761–7. https://doi.org/10.1245/s10434-020-08315-x.CrossRef

25.

Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5.CrossRefPubMed

26.

Akobeng AK. 2007 Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr Oslo Nor. 1992;96(5):644–7. https://doi.org/10.1111/j.1651-2227.2006.00178.x.CrossRef

27.

Unal I. Defining an optimal cut-point Value in ROC analysis: an alternative approach. Comput Math Methods Med. 2017;2017:3762651. https://doi.org/10.1155/2017/3762651.CrossRefPubMedPubMedCentral

28.

Beal EW, Suarez-Kelly LP, Kimbrough CW, et al. Impact of neoadjuvant chemotherapy on the outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional retrospective review. J Clin Med. 2020;9(3):748. https://doi.org/10.3390/jcm9030748.CrossRefPubMedPubMedCentral

29.

Rovers KP, Bakkers C, Nienhuijs SW, et al. Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases. JAMA Surg. 2021;156(8):1–12. https://doi.org/10.1001/jamasurg.2021.1642.CrossRefPubMedCentral

30.

Kannagi R. Carbohydrate antigen sialyl Lewis a-its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J. 2007;30(3):21.

31.

Kannagi R, Sakuma K, Miyazaki K, et al. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: clues in the ongoing search for new tumor markers. Cancer Sci. 2010;101(3):586–93. https://doi.org/10.1111/j.1349-7006.2009.01455.x.CrossRefPubMed

32.

Takada A, Ohmori K, Yoneda T, et al. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res. 1993;53(2):354–61.PubMed

33.

Miyazaki K, Ohmori K, Izawa M, et al. Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers. Cancer Res. 2004;64(13):4498–505. https://doi.org/10.1158/0008-5472.CAN-03-3614.CrossRefPubMed

34.

Rota M, Antolini L. Finding the optimal cut-point for Gaussian and Gamma distributed biomarkers. Comput Stat Data Anal. 2014;69:1–14. https://doi.org/10.1016/j.csda.2013.07.015.CrossRef

35.

Cashin PH, Graf W, Nygren P, Mahteme H. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study. Eur J Surg Oncol EJSO. 2012;38(6):509–15. https://doi.org/10.1016/j.ejso.2012.03.001.CrossRefPubMed

36.

Verwaal VJ, Boot H, Aleman BMP, van Tinteren H, Zoetmulder FAN. Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: location, treatment, and outcome. Ann Surg Oncol. 2004;11(4):375–9. https://doi.org/10.1245/ASO.2004.08.014.CrossRefPubMed

37.

Huo YR, Huang Y, Liauw W, Zhao J, Morris DL. Prognostic value of carcinoembryonic antigen (CEA), AFP, CA19-9 and CA125 for patients with colorectal cancer with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Anticancer Res. 2016;36(3):1041–9.PubMed

38.

Wu T, Mo Y, Wu C. Prognostic values of CEA, CA19-9, and CA72-4 in patients with stages I-III colorectal cancer. Int J Clin Exp Pathol. 2020;13(7):1608–14.PubMedPubMedCentral

39.

Hou S, Jing J, Wang Y, et al. Evaluation of clinical diagnostic and prognostic value of preoperative serum carcinoembryonic antigen, CA19-9, and CA24-2 for colorectal cancer. Altern Ther Health Med. 2023;29(6):192–7.PubMed

40.

Mizuno H, Miyake H, Nagai H, et al. Optimal cutoff value of preoperative CEA and CA19-9 for prognostic significance in patients with stage II/III colon cancer. Langenbecks Arch Surg. 2021;406(6):1987–97. https://doi.org/10.1007/s00423-021-02236-3.CrossRefPubMed

41.

Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(3):263–7. https://doi.org/10.1200/JCO.2011.37.1039.CrossRef

42.

Fackche N, Schmocker RK, Kubi B, et al. The utility of preoperative tumor markers in peritoneal carcinomatosis from primary appendiceal adenocarcinoma: an Analysis from the US HIPEC collaborative. J Gastrointest Surg. 2021;25(11):2908–19. https://doi.org/10.1007/s11605-021-04953-y.CrossRefPubMed

43.

Wiseman JT, Abdel-Misih S, Beal EW, et al. A multi-institutional analysis of textbook outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surg Oncol. 2021;37:101492. https://doi.org/10.1016/j.suronc.2020.11.006.CrossRefPubMed

44.

Beal EW, Ahmed A, Grotz T, et al. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg. 2020;219(3):478–83. https://doi.org/10.1016/j.amjsurg.2019.09.017.CrossRefPubMed

45.

Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102(6):576–81. https://doi.org/10.1002/jso.21679.CrossRefPubMed

Title: Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative
Authors: Nadege T. Fackche, MD
Ryan K. Schmocker, MD, MS
Richard Nudotor, MD, PMH
Boateng Kubi, BS
Jordan M. Cloyd, MD
Travis E. Grotz, MD
Keith F. Fournier, MD
Sean P. Dineen, MD
Jula Veerapong, MD
Joel M. Baumgartner, MD, MAS
Callisia N. Clarke, MD
Sameer H. Patel, MD
Gregory C. Wilson, MD
Laura A. Lambert, MD
Courtney Pokrzywa, MD
Daniel E. Abbott, MD
Byrne Lee, MD
Charles A. Staley, MD
Mohammad Y. Zaidi, MD
Fabian M. Johnston, MD, MHS
Jonathan B. Greer, MD
Publication date: 03-02-2024
Publisher: Springer International Publishing
Keywords: Cancer Biomarker
Cytostatic Therapy
Metastasis
Published in: Annals of Surgical Oncology / Issue 5/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-14890-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Preoperative CA 19-9 Predicts Disease Progression in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Analysis from the US HIPEC Collaborative

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2024

ASO Visual Abstract: Prediction of Recurrent Cervical Cancer in 2 Years Follow-Up After Treatment Based on Quantitative and Qualitative Magnetic Resonance Imaging Parameters—A Preliminary Study

ASO Author Reflections: Impact of Myosteatosis and Creatinine-to-Cystatin C Ratio on Prognosis After Pancreatic Radical Surgery

Laparoscopic Portal Vein Ligation and Embolization During First-Stage Hepatectomy for Initially Unresectable Colorectal Liver Metastases

ASO Visual Abstract: Preoperative Frailty and Malnutrition in Surgical Oncology Patients Predicts Higher Postoperative Adverse Events and Worse Survival—Results of a Blinded, Prospective Trial

Left Hepatectomy Combined with Right Hepatic Artery Resection and Reconstruction for Hilar Cholangiocarcinoma

ASO Author Reflections: Total Three-Dimensional Guided Laparoscopic Radical Resection for Perihilar Cholangiocarcinoma—Transitioning from the Plane to the Realm of Dimensionality